168 related articles for article (PubMed ID: 10487576)
1. Radiotoxicity of systemically administered 211At-labeled human/mouse chimeric monoclonal antibody: a long-term survival study with histologic analysis.
McLendon RE; Archer GE; Larsen RH; Akabani G; Bigner DD; Zalutsky MR
Int J Radiat Oncol Biol Phys; 1999 Sep; 45(2):491-9. PubMed ID: 10487576
[TBL] [Abstract][Full Text] [Related]
2. Radioimmunotherapy of neoplastic meningitis in rats using an alpha-particle-emitting immunoconjugate.
Zalutsky MR; McLendon RE; Garg PK; Archer GE; Schuster JM; Bigner DD
Cancer Res; 1994 Sep; 54(17):4719-25. PubMed ID: 8062270
[TBL] [Abstract][Full Text] [Related]
3. Clinical experience with alpha-particle emitting 211At: treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6.
Zalutsky MR; Reardon DA; Akabani G; Coleman RE; Friedman AH; Friedman HS; McLendon RE; Wong TZ; Bigner DD
J Nucl Med; 2008 Jan; 49(1):30-8. PubMed ID: 18077533
[TBL] [Abstract][Full Text] [Related]
4. Alpha-particle radiotherapy with 211At-labeled monodisperse polymer particles, 211At-labeled IgG proteins, and free 211At in a murine intraperitoneal tumor model.
Larsen RH; Hoff P; Vergote IB; Bruland OS; Aas M; De Vos L; Nustad K
Gynecol Oncol; 1995 Apr; 57(1):9-15. PubMed ID: 7705707
[TBL] [Abstract][Full Text] [Related]
5. Vascular-targeted radioimmunotherapy with the alpha-particle emitter 211At.
Kennel SJ; Mirzadeh S; Eckelman WC; Waldmann TA; Garmestani K; Yordanov AT; Stabin MG; Brechbiel MW
Radiat Res; 2002 Jun; 157(6):633-41. PubMed ID: 12005541
[TBL] [Abstract][Full Text] [Related]
6. Tissue distribution and radiation dosimetry of astatine-211-labeled chimeric 81C6, an alpha-particle-emitting immunoconjugate.
Zalutsky MR; Stabin MG; Larsen RH; Bigner DD
Nucl Med Biol; 1997 Apr; 24(3):255-61. PubMed ID: 9228660
[TBL] [Abstract][Full Text] [Related]
7. The development of a [211AT]-astatinated endoradiotherapeutic drug: part IV--late radiation effects.
Brown I; Mitchell JS
Int J Radiat Oncol Biol Phys; 1998 Mar; 40(5):1177-83. PubMed ID: 9539575
[TBL] [Abstract][Full Text] [Related]
8. Radiotoxicity of systematically administered [211At]astatide in B6C3F1 and BALB/c (nu/nu) mice: a long-term survival study with histologic analysis.
McLendon RE; Archer GE; Garg PK; Bigner DD; Zalutsky MR
Int J Radiat Oncol Biol Phys; 1996 Apr; 35(1):69-80. PubMed ID: 8641929
[TBL] [Abstract][Full Text] [Related]
9. Cytotoxicity of alpha-particle-emitting astatine-211-labelled antibody in tumour spheroids: no effect of hyperthermia.
Hauck ML; Larsen RH; Welsh PC; Zalutsky MR
Br J Cancer; 1998 Mar; 77(5):753-9. PubMed ID: 9514054
[TBL] [Abstract][Full Text] [Related]
10. The cytotoxicity and microdosimetry of astatine-211-labeled chimeric monoclonal antibodies in human glioma and melanoma cells in vitro.
Larsen RH; Akabani G; Welsh P; Zalutsky MR
Radiat Res; 1998 Feb; 149(2):155-62. PubMed ID: 9457895
[TBL] [Abstract][Full Text] [Related]
11. Astatine-211-labeled radiotherapeutics: an emerging approach to targeted alpha-particle radiotherapy.
Zalutsky MR; Vaidyanathan G
Curr Pharm Des; 2000 Sep; 6(14):1433-55. PubMed ID: 10903402
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic efficacy of astatine-211-labeled trastuzumab on radioresistant SKOV-3 tumors in nude mice.
Palm S; Bäck T; Claesson I; Danielsson A; Elgqvist J; Frost S; Hultborn R; Jensen H; Lindegren S; Jacobsson L
Int J Radiat Oncol Biol Phys; 2007 Oct; 69(2):572-9. PubMed ID: 17869670
[TBL] [Abstract][Full Text] [Related]
13. Labeling monoclonal antibodies and F(ab')2 fragments with the alpha-particle-emitting nuclide astatine-211: preservation of immunoreactivity and in vivo localizing capacity.
Zalutsky MR; Garg PK; Friedman HS; Bigner DD
Proc Natl Acad Sci U S A; 1989 Sep; 86(18):7149-53. PubMed ID: 2476813
[TBL] [Abstract][Full Text] [Related]
14. The development of a [211At]-astatinated endoradiotherapeutic drug: Part II. Therapeutic results for transplanted adenocarcinoma of the rectum in mice and associated studies.
Brown I; Mitchell JS
Int J Radiat Oncol Biol Phys; 1994 Apr; 29(1):115-24. PubMed ID: 8175418
[TBL] [Abstract][Full Text] [Related]
15. Astatine-211 labeling of internalizing anti-EGFRvIII monoclonal antibody using N-succinimidyl 5-[211At]astato-3-pyridinecarboxylate.
Reist CJ; Foulon CF; Alston K; Bigner DD; Zalutsky MR
Nucl Med Biol; 1999 May; 26(4):405-11. PubMed ID: 10382844
[TBL] [Abstract][Full Text] [Related]
16. Administered activity and metastatic cure probability during radioimmunotherapy of ovarian cancer in nude mice with 211At-MX35 F(ab')2.
Elgqvist J; Andersson H; Bernhardt P; Bäck T; Claesson I; Hultborn R; Jensen H; Johansson BR; Lindegren S; Olsson M; Palm S; Warnhammar E; Jacobsson L
Int J Radiat Oncol Biol Phys; 2006 Nov; 66(4):1228-37. PubMed ID: 17145538
[TBL] [Abstract][Full Text] [Related]
17. High-level production of alpha-particle-emitting (211)At and preparation of (211)At-labeled antibodies for clinical use.
Zalutsky MR; Zhao XG; Alston KL; Bigner D
J Nucl Med; 2001 Oct; 42(10):1508-15. PubMed ID: 11585865
[TBL] [Abstract][Full Text] [Related]
18. Labeling Monoclonal Antibody with α-emitting
Vaidyanathan G; Pozzi OR; Choi J; Zhao XG; Murphy S; Zalutsky MR
Cancer Biother Radiopharm; 2020 Sep; 35(7):511-519. PubMed ID: 32109139
[No Abstract] [Full Text] [Related]
19. Targeted alpha-particle radiotherapy with 211At-labeled monoclonal antibodies.
Zalutsky MR; Reardon DA; Pozzi OR; Vaidyanathan G; Bigner DD
Nucl Med Biol; 2007 Oct; 34(7):779-85. PubMed ID: 17921029
[TBL] [Abstract][Full Text] [Related]
20. Phase I trial results of iodine-131-labeled antitenascin monoclonal antibody 81C6 treatment of patients with newly diagnosed malignant gliomas.
Cokgor I; Akabani G; Kuan CT; Friedman HS; Friedman AH; Coleman RE; McLendon RE; Bigner SH; Zhao XG; Garcia-Turner AM; Pegram CN; Wikstrand CJ; Shafman TD; Herndon JE; Provenzale JM; Zalutsky MR; Bigner DD
J Clin Oncol; 2000 Nov; 18(22):3862-72. PubMed ID: 11078500
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
